Dr. Reddy's Laboratories Limited (RDY)

NYQ – Real Time Price. Currency in USD

12.36

-0.09 (-0.68%)

Market open: Aug 12, 2026, 1:15 PM EDT

12.45

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

06.08.2026

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

04.08.2026

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bridion--Dr. Reddy's Laboratories today announced launch of Sugammadex Injection of Single-Dose Vials, a generic equivalent of Bridion®, in the United States.

Videos

No Data

There is no data to display

Press releases

06.08.2026

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

04.08.2026

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Dr. Reddy's Laboratories Limited (RDY)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Dr. Reddy's Laboratories Limited (RDY)

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Videos

No Data

Press releases

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Videos

No Data

Press releases

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Search stocks

Dr. Reddy's Laboratories Limited (RDY)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Dr. Reddy's Laboratories Limited (RDY)

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Videos

No Data

Press releases

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Videos

No Data

Press releases

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States